<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03275285</url>
  </required_header>
  <id_info>
    <org_study_id>EFC15246</org_study_id>
    <secondary_id>2017-001940-37</secondary_id>
    <secondary_id>U1111-1195-5957</secondary_id>
    <nct_id>NCT03275285</nct_id>
  </id_info>
  <brief_title>Multinational Clinical Study Comparing Isatuximab, Carfilzomib And Dexamethasone To Carfilzomib And Dexamethasone In Relapse And/Or Refractory Multiple Myeloma Patients</brief_title>
  <acronym>IKEMA</acronym>
  <official_title>Randomized, Open Label, Multicenter Study Assessing The Clinical Benefit Of Isatuximab Combined With Carfilzomib (KyprolisÂ®) And Dexamethasone Versus Carfilzomib With Dexamethasone In Patients With Relapse And/Or Refractory Multiple Myeloma Previously Treated With 1 to 3 Prior Lines</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary Objective:

      To demonstrate the benefit of isatuximab in combination with carfilzomib and dexamethasone in
      the prolongation of Progression Free Survival (PFS) as compared to carfilzomib and
      dexamethasone in patients with relapsed and/or refractory multiple myeloma (MM) previously
      treated with 1 to 3 lines of therapy.

      Secondary Objectives:

        -  To evaluate the Overall Response Rate (ORR), rate of very good partial response (VGPR)
           or better and complete response (CR) rate in both arms using International Myeloma
           Working Group (IMWG) criteria.

        -  To evaluate rate of VGPR or better with minimal residual disease (MRD) negativity in
           both arms using IMWG criteria.

        -  To evaluate the Overall Survival (OS) in both arms.

        -  To evaluate safety in both arms.

        -  To evaluate duration of response (DOR) in both arms.

        -  To evaluate the Time To Progression (TTP) in both arms.

        -  To evaluate the Second Progression Free Survival (PFS2) in both arms.

        -  To determine the Pharmacokinetic profile of isatuximab in combination with carfilzomib.

        -  To evaluate the immunogenicity of isatuximab in isatuximab arm.

        -  To assess disease-specific and generic health-related quality of life (HRQL), disease
           and treatment-related symptoms, health state utility, and health status in both arms.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The duration of the study for the patients will include a period for screening of up to 3
      weeks. Patients will continue study treatment until disease progression, unacceptable adverse
      reaction, patients' wish or other reason of discontinuation. During follow-up, patients who
      discontinue the study treatment due to progression of the disease will be followed every 3
      months (12 weeks) for further anti-myeloma therapies, progression free survival to the second
      progression and survival, until death or the cut-off date, whichever comes first. Patients
      who discontinue the study treatment prior to documentation of disease progression will be
      followed-up every 4 weeks until confirmation of disease progression, and then every 3 months
      (12 weeks) for further anti-myeloma therapies, progression free survival to the second
      progression and survival, until death or the cut-off date, whichever comes first. After
      progression free survival analysis, patients will be followed yearly for 3 years for
      survival.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 19, 2017</start_date>
  <completion_date type="Anticipated">November 2023</completion_date>
  <primary_completion_date type="Anticipated">November 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression Free Survival (PFS)</measure>
    <time_frame>Up to approximately 36 months</time_frame>
    <description>The length of time between treatment allocation and a patient lives with the disease but it does not get worse</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Response Rate (ORR)</measure>
    <time_frame>Up to approximately 36 months</time_frame>
    <description>The proportion of patients that have a response to their disease: stringent complete response (sCR), complete response (CR), very good partial response (VGPR) or partial response (PR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of VGPR or better</measure>
    <time_frame>Up to approximately 36 months</time_frame>
    <description>The proportion of patients with sCR, CR and VGPR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CR rate</measure>
    <time_frame>Up to approximately 36 months</time_frame>
    <description>The proportion of patients with sCR and CR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of VGPR or better with MRD (Minimal Residual Disease) negativity</measure>
    <time_frame>Up to approximately 36 months</time_frame>
    <description>The proportion of patients with VGPR, CR or sCR and for whom MRD assessed by sequencing is negative</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>Up to approximately 72 months</time_frame>
    <description>The length of time from the treatment allocation for a disease that patients are still alive</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Progression (TTP)</measure>
    <time_frame>Up to approximately 36 months</time_frame>
    <description>How long the study treatment last before disease progression occurs</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Second Progression Free Survival (PFS2)</measure>
    <time_frame>Up to approximately 36 months</time_frame>
    <description>The length of time between treatment allocation and second progression disease</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response (DOR)</measure>
    <time_frame>Up to approximately 36 months</time_frame>
    <description>How long from the first response is observed until disease progression</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with adverse events according to the National Cancer Institute - Common Toxicity Criteria (NCI- CTC) version 4.03 grading scaling</measure>
    <time_frame>Up to 30 days after last study treatment administration</time_frame>
    <description>To evaluate how many adverse events occur while taking study treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient-reported outcome measured with Quality of Life questionnaire</measure>
    <time_frame>Screening to 90 days after last study treatment administration</time_frame>
    <description>To evaluate change in your daily activities from screening</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of isatuximab</measure>
    <time_frame>Up to approximately 10 months</time_frame>
    <description>To evaluate the plasma concentration of isatuximab</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of carfilzomib</measure>
    <time_frame>Up to 1 month</time_frame>
    <description>To evaluate the plasma concentration of carfilzomib in 12 patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity (ADA)</measure>
    <time_frame>Up to 13 months</time_frame>
    <description>To evaluate presence of anti-drug antibodies against isatuximab</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Plasma Cell Myeloma</condition>
  <arm_group>
    <arm_group_label>Isatuximab + Carfilzomib + Dexamethasone (IKd)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Isatuximab (intravenous) on day 1, 8, 15 and 22 of 1st cycle, then on day 1 and 15 of subsequent cycles in combination with carfilzomib (intravenous) on day 1, 2, 8, 9, 15 and 16 + dexamethasone (intravenous or by mouth [po]) on day 1, 2, 8, 9, 15, 16, 22 and 23 of a 28 day cycle</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Carfilzomib + Dexamethasone (Kd)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Carfilzomib (intravenous) on day 1, 2, 8, 9, 15, 16 + dexamethasone (intravenous or po) on day 1, 2, 8, 9, 15, 16, 22 and 23 of a 28 day cycle</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>isatuximab SAR650984</intervention_name>
    <description>Pharmaceutical form: solution for infusion
Route of administration: intravenous</description>
    <arm_group_label>Isatuximab + Carfilzomib + Dexamethasone (IKd)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>carfilzomib</intervention_name>
    <description>Pharmaceutical form: solution for infusion
Route of administration: intravenous</description>
    <arm_group_label>Carfilzomib + Dexamethasone (Kd)</arm_group_label>
    <arm_group_label>Isatuximab + Carfilzomib + Dexamethasone (IKd)</arm_group_label>
    <other_name>Kyprolis</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dexamethasone</intervention_name>
    <description>Pharmaceutical form: tablets or solution for infusion
Route of administration: oral or intravenous</description>
    <arm_group_label>Carfilzomib + Dexamethasone (Kd)</arm_group_label>
    <arm_group_label>Isatuximab + Carfilzomib + Dexamethasone (IKd)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Patients with multiple myeloma previously treated with prior 1 to 3 lines and with
             measurable serum M-protein (â¥ 0.5 g/dL) and/or urine M-protein (â¥ 200 mg/24 hours).

        Exclusion criteria:

          -  Patients previously pretreated with carfilzomib, who never achieved at least one minor
             response during previous therapies and/or last previous therapy completed within 14
             last days.

          -  Patients with serum free light chain (FLC) measurable disease only.

          -  Patients less than 18 years old, patients with Eastern Cooperative Oncology Group
             performance status more than 2.

          -  Patients with inadequate biological tests.

          -  Patients with myocardial infarction, severe/unstable angina pectoris,
             coronary/peripheral artery bypass graft, New York Heart Association class III or IV
             congestive heart failure, superior or equal to grade 3 arrhythmias, stroke or
             transient ischemic attack within last 6 months, and/or left ventricular ejection
             fraction lower than 40%.

          -  Patients with previous cancer unless disease free for more than 5 years or in situ
             cancer curatively treated.

          -  Patients with known acquired immunodeficiency syndrome related illness (AIDS) or human
             immunodeficiency virus (HIV) requiring antiretroviral treatment, or hepatitis A, B, or
             C active infection.

          -  Women of childbearing potential or male patient with women of childbearing potential
             who do not agree to use highly effective method of birth control.

        The above information is not intended to contain all considerations relevant to a patient's
        potential participation in a clinical trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Sciences &amp; Operations</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>For site information, send an email with site number to</last_name>
    <email>Contact-Us@sanofi.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Investigational Site Number 0360005</name>
      <address>
        <city>Blacktown</city>
        <zip>2148</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 0360003</name>
      <address>
        <city>Clayton</city>
        <zip>3168</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 0360001</name>
      <address>
        <city>Fitzroy</city>
        <zip>3065</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 0360004</name>
      <address>
        <city>Heidelberg West</city>
        <zip>3081</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 0360007</name>
      <address>
        <city>Nedlands</city>
        <zip>6009</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 0360008</name>
      <address>
        <city>Nedlands</city>
        <zip>6009</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 0360006</name>
      <address>
        <city>Tweed Heads</city>
        <zip>2485</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 0360002</name>
      <address>
        <city>Wollongong</city>
        <zip>2500</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 0760001</name>
      <address>
        <city>Barretos</city>
        <zip>14784-400</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 0760003</name>
      <address>
        <city>Porto Alegre</city>
        <zip>90470-340</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 0760005</name>
      <address>
        <city>Salvador</city>
        <zip>40110-090</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 0760002</name>
      <address>
        <city>Sao Paulo</city>
        <zip>05403-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 1240002</name>
      <address>
        <city>Montreal</city>
        <zip>H1T 2M4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 1240001</name>
      <address>
        <city>Saint John</city>
        <zip>E2L 4L2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 2030002</name>
      <address>
        <city>Brno</city>
        <zip>62500</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 2030004</name>
      <address>
        <city>Olomouc</city>
        <zip>77900</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 2030003</name>
      <address>
        <city>Ostrava - Poruba</city>
        <zip>70852</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 2030005</name>
      <address>
        <city>Praha 10</city>
        <zip>10034</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 2030001</name>
      <address>
        <city>Praha 2</city>
        <zip>12808</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 2500003</name>
      <address>
        <city>Lille</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 2500001</name>
      <address>
        <city>Nantes Cedex 01</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 2500006</name>
      <address>
        <city>Paris Cedex 12</city>
        <zip>75571</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 2500002</name>
      <address>
        <city>Pessac</city>
        <zip>33604</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 2500005</name>
      <address>
        <city>Pierre Benite</city>
        <zip>69310</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 2500004</name>
      <address>
        <city>Poitiers</city>
        <zip>86000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 3000001</name>
      <address>
        <city>Athens</city>
        <zip>11538</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 3000002</name>
      <address>
        <city>Athens</city>
        <zip>19676</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 3000004</name>
      <address>
        <city>Patras</city>
        <zip>26500</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 3000003</name>
      <address>
        <city>Thessaloniki</city>
        <zip>57010</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 3480003</name>
      <address>
        <city>Budapest</city>
        <zip>1083</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 3480001</name>
      <address>
        <city>Budapest</city>
        <zip>1097</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 3480004</name>
      <address>
        <city>Budapest</city>
        <zip>1125</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 3480005</name>
      <address>
        <city>KaposvÃ¡r</city>
        <zip>7400</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 3800003</name>
      <address>
        <city>Bologna</city>
        <zip>40138</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 3800001</name>
      <address>
        <city>Pisa</city>
        <zip>56126</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 3800004</name>
      <address>
        <city>Reggio Emilia</city>
        <zip>42123</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 3920007</name>
      <address>
        <city>Kumamoto-Shi</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 3920005</name>
      <address>
        <city>Morioka-Shi</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 3920004</name>
      <address>
        <city>Shibuya-Ku</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 3920006</name>
      <address>
        <city>Shinjuku-Ku</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 3920003</name>
      <address>
        <city>Sunto-Gun</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 3920001</name>
      <address>
        <city>Suwa-Shi</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 3920002</name>
      <address>
        <city>Yamagata-Shi</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 4100006</name>
      <address>
        <city>Busan</city>
        <zip>49201</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 4100001</name>
      <address>
        <city>Seoul</city>
        <zip>03080</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 4100004</name>
      <address>
        <city>Seoul</city>
        <zip>03722</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 4100003</name>
      <address>
        <city>Seoul</city>
        <zip>05505</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 4100002</name>
      <address>
        <city>Seoul</city>
        <zip>06351</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 4100005</name>
      <address>
        <city>Seoul</city>
        <zip>06591</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 5540001</name>
      <address>
        <city>Auckland</city>
        <zip>2025</zip>
        <country>New Zealand</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 5540002</name>
      <address>
        <city>Wellington</city>
        <zip>6021</zip>
        <country>New Zealand</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 6430002</name>
      <address>
        <city>Ekaterinburg</city>
        <zip>620102</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 6430003</name>
      <address>
        <city>Kirov</city>
        <zip>610000</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 6430004</name>
      <address>
        <city>Novosibirsk</city>
        <zip>630047</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 7240001</name>
      <address>
        <city>Badalona</city>
        <zip>08916</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 7240005</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 7240003</name>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 7240004</name>
      <address>
        <city>Sevilla</city>
        <zip>41013</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 7240002</name>
      <address>
        <city>Valencia</city>
        <zip>46017</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 7920003</name>
      <address>
        <city>Adana</city>
        <zip>01250</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 7920001</name>
      <address>
        <city>Ankara</city>
        <zip>06500</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 7920005</name>
      <address>
        <city>Bursa</city>
        <zip>16059</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 7920002</name>
      <address>
        <city>Ä°stanbul</city>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 7920004</name>
      <address>
        <city>Samsun</city>
        <zip>55139</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8260001</name>
      <address>
        <city>Bristol</city>
        <zip>BS2 8ED</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8260005</name>
      <address>
        <city>Leicester</city>
        <zip>LE1 5WW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8260004</name>
      <address>
        <city>Plymouth</city>
        <zip>PL6 8DH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Brazil</country>
    <country>Canada</country>
    <country>Czechia</country>
    <country>France</country>
    <country>Greece</country>
    <country>Hungary</country>
    <country>Italy</country>
    <country>Japan</country>
    <country>Korea, Republic of</country>
    <country>New Zealand</country>
    <country>Russian Federation</country>
    <country>Spain</country>
    <country>Turkey</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 5, 2017</study_first_submitted>
  <study_first_submitted_qc>September 5, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">September 7, 2017</study_first_posted>
  <last_update_submitted>May 15, 2018</last_update_submitted>
  <last_update_submitted_qc>May 15, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 16, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>BB 1101</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://www.clinicalstudydatarequest.com/</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

